Amgen (United States)

Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care

Abhinav Sharma, Robert A. Harrington, Mark McClellan et al.

2018 · 334 Zit.

Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia

Jean-Luc Canon, Johan Vansteenkiste, G. Bodoky et al.

2006 · 104 Zit.

Machine Learning Approaches to Predict Asthma Exacerbations: A Narrative Review

Néstor A. Molfino, Gianluca Turcatel, Daniel J. Riskin

2023 · 41 Zit.

Economic considerations for the use of recombinant human bone morphogenetic protein‐2 in open tibial fractures in Europe: the German model

Volker Alt, Andreas Heißel

2006 · 32 Zit.

Erythropoietin deficiency after coronary artery bypass procedures

Edward A. Levine, Arthur L. Rosen, Lakshman R. Sehgal et al.

1991 · 24 Zit.

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia

Enrique Hernández, Peter Ganly, Veena Charu et al.

2009 · 23 Zit.

Análisis de coste-efectividad de la administración de darbepoetina alfa una vez cada tres semanas frente a su administración semanal en el tratamiento de la anemia inducida por quimioterapia

M. del Roser Guardia Riera, Ferran Pérez, Ana Vieta et al.

2008 · 0 Zit.

Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits

Jerrold Hill, Sanatan Shreay, November McGarvey et al.

2013 · 0 Zit.

Reply: Clarifying validation and statistical aspects of AI‑based risk prediction in liver disease

Peng Zhang, Grace L. Su

2025 · 0 Zit.